Speaker Profile

Ph.D., Founder, 54Gene

Biography
Dr. Abasi Ene-Obong is the Founder of 54gene. He is a seasoned business leader with extensive experience in the US, UK and Nigerian healthcare industries. Among other notable mentions, Dr. Ene-Obong has been recognised as one of Africa’s young innovators, one of Fortune’s 40 under 40 most influential people in healthcare and is a Bloomberg Catalyst in recognition of his contributions towards accelerating solutions to global health problems. 54gene is a health technology company equalizing precision medicine for Africans and the global population through innovative scientific research, advanced molecular diagnostics and clinical studies. The company is working to ensure that Africa, a genetically diverse population, is adequately represented in drug discovery and other clinical research.


 Session Abstract – PMWC 2023 Silicon Valley

Track 2 - January 26 9.00 A.M.-4.30 P.M.


Track Chair: - Courtney McFall, UCSF
- Ben Rubin, UCSF

Patient-centric data – Real-World Evidence (RWE) and Real-World Data (RWD) - is becoming instrumental in the drug development process and for health care decisions in general. This data is not only informative for the process from discovery to new indications, clinical trial design, and drug development, it also can be of value to monitor post-marketing drug safety and for decision support in clinical practice. As the data becomes a decision driver, science companies and medical organizations are increasingly focused on leveraging RWD and RWE to not only better understand the patient populations using their drugs and the respective outcomes, but also to accelerate clinical decision support. This session will focus on the various aspects of integrating RWE and RWD to support drug development and clinical decision support.

Sessions:

  • Clinical Studies Using RWD (PANEL)
    Chair: Aaron Kamauu, Navidence
    - Liora Schultz, Stanford
    - Sanket Dhurva, UCSF
    - Eze Abosi, Optum Life Sciences
    - Motiur Rahman, FDA
    - Atul Butte, UCSF
  • Beyond the EHR: Acquisition of RWD Types to Enable Precision Medicine (PANEL)
    Chair: Riley Bove, UCSF
    - Anna Berry, Sypase
    - Ashley Brenton, Optum
    - Vasu Chandrasekaran, Ontada
  • Data Linkage, Harmonization, and Quality (PANEL)
    Chair: Vivek Rudrapatna, UCSF
    - Rohit Vashisht, UCSF
    - Adam Asare, QLHC
    - Dan Riskin, Verantos
    - Wanmei Ou, Ontada
    - Mindy DeRouen, UCSF
    - Saurabh Gombar, Atropos Health
  • Using RWE to Uncover and Address Health Disparities (PANEL)
    Chair: Chris Boone, AbbVie
    - Robert Hiatt, UCSF
    - Abasi Ene-Obong, 54gene
    - Nuray Yurt, Novartis Oncology
    - Alice Popejoy, UC Davis Health
    - Vic Spain, Genentech
  • FDA RWD/RWE Draft and Final Guidances
    - Motiur Rahman, FDA
  • Fireside Chat:
    - Vivek Rudrapatna, UCSF
    - Keith Yamamoto, UCSF
    - Hilary Marston, FDA
  • From Real-World Data to Regulatory-Grade Real-World Evidence
    Chair: Sheila Walcoff, Goldbug Strategies
    - Elaine Katrivanos, Tempus
    - Kathy Hibbs, 23andMe